Does Xeljanz cause weight gain?
Why is weight loss while taking Xeljanz a concern? Does body weight affect the dose of Xeljanz?
Xeljanz (tofacitinib citrate) is a Janus kinase (JAK) inhibitor used in the treatment of rheumatoid arthritis, psoriatic arthritis, polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis and ulcerative colitis. It is a disease-modifying anti-rheumatic drug (DMARD) and a small molecule drug, rather than a biological agent.
Weight gain and weight loss were not identified as side effects during clinical development of Xeljanz.
Why is weight loss while taking Xeljanz a concern?
While not a direct side effect of Xeljanz, it’s important to keep an eye on unexplained weight loss while taking the drug. Xeljanz affects the immune system and lowers your ability to fight off serious infections, such as tuberculosis (TB). TB can cause weight loss, as well as other symptoms of an infection.
Weight loss can also be a symptom of ulcerative colitis.
Does body weight affect the dose of Xeljanz?
Children taking Xeljanz for polyarticular course juvenile idiopathic arthritis will need their dosage adjusted if they weigh less than 40kg. Xeljanz 5mg twice a day is recommended for those weighing 40kg or more, which can be given in the form of a tablet or oral solution.
A 4ml (4mg) dose of the Xeljanz oral solution given twice daily is recommended for patients weighing ≥20kg and ﹤40kg, while a 3.2ml dose given twice a day is recommended for patients weighing ≥10kg and ﹤20kg.
A tablet, extended-release tablet and oral solution formulations of Xeljanz have been approved by the US Food and Drug Administration (FDA).
References
- Food and Drug Administration (FDA). Xeljanz / Xeljanz XR / Xeljanz Oral Solution. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203214s028,208246s013,213082s003lbl.pdf. [Accessed December 17, 2021].
Read next
What are JAK inhibitors and how do they work?
Janus kinase (JAK) inhibitors are a group of medicines that help block immune system signals in the body that can lead to swelling (inflammation) and pain in conditions like rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis. They work by blocking enzymes that lead to overactivity of the immune system. Continue reading
Which JAK inhibitors are approved in the U.S?
List of JAK inhibitors approved in the United States include:
- Cibinqo (abrocitinib)
- Inrebic (fedratinib)
- Jakafi (ruxolitinib)
- Litfulo (ritlecitinib)
- Ojjaara (momelotinib)
- Olumiant (baricitinib)
- Opzelura (ruxolitinib)
- Rinvoq (upadacitinib)
- Vonjo (pacritinib)
- Xeljanz (tofacitinib)
What happens when you stop taking Xeljanz?
Stopping treatment with Xeljanz may cause the symptoms of your condition to return. However, some patients are able to stop Xeljanz without their symptoms flaring up, according to the results of research conducted in patients with rheumatoid arthritis. You should not stop taking Xeljanz without consulting your doctor. Continue reading
Related medical questions
- What are the new drugs for rheumatoid arthritis (RA)?
- How long does Xeljanz take to work?
- Does Xeljanz cause hair loss?
- Can I drink alcohol while taking Xeljanz?
- What is Xeljanz used for and is it a biologic?
- Is Xeljanz an immunosuppressant?
- Can you take Xeljanz with antibiotics and antifungals?
- Does Xeljanz cause high blood pressure?
- Who makes Xeljanz and where is it made?
- Is Xeljanz approved for ankylosing spondylitis?
Drug information
- Xeljanz Information for Consumers
- Xeljanz prescribing info & package insert (for Health Professionals)
- Side Effects of Xeljanz (detailed)
- Xeljanz user reviews (145)
Related support groups
- Xeljanz (22 questions, 38 members)
- Weight Loss (Obesity/Overweight) (846 questions, 1,505 members)